Business Context and Reporting Period
Company: SANUWAVE Health, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 27, 2017
Event: Entry into a Material Definitive Agreement (Binding Term Sheet) with MundiMed Distribuidora Hospitalar LTDA ("MundiMed").
Key Financial Metrics
The filing does not provide standard financial statements (revenue, profit, cash flow, margins, debt, or liquidity) for the reporting period. The document focuses exclusively on the terms of a new commercial agreement.
- Initial Partnership Fee: Payable by MundiMed on September 30, 2017 (specific amount not disclosed).
- Recurring Fees: Monthly partnership fees payable over 18 months (specific amounts not disclosed).
- Estimated Start-up Costs: Expected not to exceed $200,000, borne by MundiMed.
- Projected Device Sales: MundiMed to purchase 2 to 6 dermaPACE devices by December 31, 2017 (specific unit price not disclosed).
Material Changes and Agreement Terms
The primary material change is the formation of a joint venture for the manufacture, sale, and distribution of the Company's dermaPACE device in the target market.
- Profit Distribution: 45% to SANUWAVE Health, Inc., 45% to MundiMed, and 5% each to advisors LHS Latina Health Solutions Gestão Empresarial Ltda. and Universus Global Advisors LLC.
- Binding Status: The Term Sheet becomes binding if a definitive agreement is not executed by September 30, 2017.
- Termination: The agreement terminates upon execution of a definitive agreement or May 30, 2019, whichever is earlier.
- Legal Jurisdiction: Governed by the laws of the State of New York.
Outlook, Risks, and Contingencies
Management Commentary: The Company intends to submit a Confidential Treatment Request to the SEC to redact certain portions of the Binding Term Sheet in its upcoming Form 10-Q.
Risks and Contingencies:
- Definitive Agreement Risk: While the Term Sheet is binding if not superseded by September 30, 2017, the ultimate commercial success depends on the execution of a definitive agreement reflecting these terms.
- Redaction: Full details of the agreement are not currently public due to pending confidential treatment requests.
- Experimental Use: Initial device purchases are designated for experimental, pre-approved work, implying limited immediate commercial scale.
Investor Verification Checklist
- Verify the specific dollar amounts of the initial and monthly partnership fees in the upcoming Form 10-Q.
- Confirm the execution of the definitive agreement by September 30, 2017.
- Monitor the actual number of dermaPACE devices purchased by MundiMed by December 31, 2017.
- Review the redacted Binding Term Sheet filed as an exhibit to the Form 10-Q for undisclosed material terms.
- Assess the financial impact of the 5% advisor fees on net profit distribution.